ReachRxResearch
Home
Research
Sign Up
Study limitation
Back to Research Hub
  1. Home
  2. Research Hub
  3. Study limitation

Atacicept in IgA Nephropathy — Phase 3 Trial Final Efficacy Analysis

Study limitation reported by the research below: “Placebo group showed an unexpectedly rapid eGFR decline (-5.69 mL/min/1.73 m² at 52 weeks), which may reflect a higher-risk population and limit generalizability to all IgA nephropathy patients.”

Papers